CRVS Historical PE Ratio Notes

— Corvus Pharmaceuticals, Inc. (ticker symbol: CRVS) is a clinical-stage biopharmaceutical company focused on the development & commercialization of novel immuno-oncology therapies that target the immune system to treat cancers. Their lead product candidates, such as mupadolimab (an anti-CD73 antibody) and ciforadenant (an adenosine A2A receptor antagonist), are designed to enhance antitumor immune responses, and the company frequently reports updates on their progress in clinical trials for difficult-to-treat cancers. For investors, it’s important to note that as a pre-revenue biotech firm, Corvus Pharma has historically reported negative earnings, which directly impacts its historical price-to-earnings (PE) ratio. In many periods, CRVS will show either a non-meaningful or negative PE ratio due to a lack of net profits—a common characteristic for early-stage drug development companies still in R&D mode and without commercialized products. When reviewing historical charts and tables for price, earnings, and PE ratio, realize that any movement in the ratio will largely correspond to changes in net losses versus stock price moves, rather than reliable patterns of profitability. This means historical PE may not be a useful valuation measure until (and if) Corvus generates sustained earnings from successful therapies.

On this page we presented the Corvus Pharma Historical PE Ratio information for Corvus Pharma' stock. The average CRVS historical PE based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is NA. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average CRVS historical PE based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this CRVS historical PE result, against the recent PE: when this page was posted on 5/19/2026, the most recent closing price for CRVS had been 11.50, and the most recent quarterly earnings result, annualized, was NA. Meanwhile, the most recent TTM earnings summed to NA.

For self directed investors doing their due diligence on CRVS or any other given stock, valuation analysis for CRVS can greatly benefit from studying the past earnings and resulting PE calculations. This exercise can help inform an analysis as to whether the past earnings trajectory and current versus historical PE ratios justify the current stock value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Corvus Pharma PE history or the past PE information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for CRVS. Thanks for visiting, and the next time you need to research CRVS Historical PE Ratio or the ratio for another stock, we hope you'll think of our site, as your go-to historical PE ratio research resource of choice.